To examine the role of FGFR alterations on drug resistance in patients, we analyzed post-progression circulating tumor DNA (ctDNA) from 34 patients with ER+/HER2− breast cancer treated with palbociclib plus endocrine therapy. This evidence concerns the gene ESR1 and breast carcinoma.